Barron’sClovis Oncology has delivered big results in a much-waited late-stage clinical trial for its ovarian cancer drug. Is a takeover on the horizon? By. Johanna Bennett. June 19, 2017 10:36 a.m. ET. Text Size; Regular; Medium; Large. Talk about good timing.Clovis Oncology’s 45% Pre-Market Surge, Explained ..
Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval
Endpoints NewsCHICAGO — Loxo Oncology made it into the ASCO showcase over the weekend, boasting of a small but growing number of cases where children and adults with TRK fusion cancer responded to their lead drug, larotrectinib (LOXO-101). And they’re …Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195 ..
ASCO17: Loxo shows promise of biomarker approach to cancer
ForbesNew research presented at this weekend’s annual meeting of the American Society of Clinical Oncology (ASCO) points toward the hastening development of precision medicine in cancer research, a concept which promises to upend the traditional …Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195 ..
Prepping for FDA filing, Loxo rolls up data on its site-agnostic cancer med larotrectinib
FierceBiotechAt the ASCO meeting in Chicago on Saturday, Loxo Oncology rolled out response-rate data on the site-agnostic cancer med it hopes to get to the FDA by early 2018. Share Facebook Twitter LinkedIn Email Print. CHICAGO—When Merck & Co.’s Keytruda won …Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195 ..
Clovis Oncology stock surges 50% on positive late-stage cancer trial results
UtahHerald.comClovis Oncology Inc. CLVS, +0.45% shares surged 50% in premarket trade Monday after the company said its late-stage trial for a cancer drug met its primary endpoint and a key secondary endpoint. Clovis said it plans to try for Food and Drug Clovis’s ovarian cancer drug set for label expansion, shares soar ..
Roche therapy reduces risk of invasive breast cancer returning -trial
ZURICH, June 5 Roche Holding said a late-stage clinical trial had shown its Perjeta-based regimen reduced the risk of invasive cancer returning compared to standard therapy in a kind of early breast cancer. A combination of Perjeta, Herceptin and … ..
ProShare Advisors LLC Has $565000 Stake in Loxo Oncology Inc (LOXO)
ForbesLoxo Oncology logo ProShare Advisors LLC cut its position in Loxo Oncology Inc (NASDAQ:LOXO) by 18.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,425 shares of the biopharmaceutical company’s …Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195 ..
IBM Unveils New Watson Oncology Data at ASCO 2017
R & D MagazineIBM’s Watson Health Unit revealed new findings on Friday at the annual American Society for Clinical Oncology meeting that could lay the groundwork for future supercomputing applications in healthcare. Investigators presented results from five studies …Studies show IBM Watson reaches mostly same cancer decisions as doctors ..
Clovis’s ovarian cancer drug set for label expansion, shares soar
Investor’s Business Daily… * Co to apply for U.S. drug label expansion within 4 mths * Shares up 48 pct at $88.50 in premarket trade * Rival Tesaro’s shares down 16.8 pct (Adds shares, details on class action lawsuit) By Natalie GroverJune 19 (Reuters) – Positive late-stage Clovis Oncology’s 45% Pre-Market Surge, Explained ..